Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 265 matching trials from the live ClinicalTrials.gov search.
Conditions
Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
leucovorin calcium, bevacizumab, cholecalciferol, fluorouracil, oxaliplatin, pharmacological study
Drug · Biological · Dietary Supplement + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Gastrointestinal Cancer
Interventions
Oxaliplatin, Capecitabine, Leucovorin, 5-fluorouracil, radiation
Drug · Radiation
Lead sponsor
Tannaz Armaghany
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Houston, Texas
Conditions
Rectal Cancer
Interventions
FOLFOXIRI, FOLFOX regimen, XELOX, IMRT
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Conditions
Advanced Rectal Cancer
Interventions
FOLFOX
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Rochester, New York
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Conditions
Colorectal Neoplasm, Hepatic Neoplasm
Interventions
DCE-MRI
Other
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Solid Tumors
Interventions
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX, FOLFOX, FOLFIRI, INCA33890
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more
Conditions
Adenocarcinoma
Interventions
Trastuzumab, ABT-806, Bemarituzumab, Ramucirumab, Nivolumab, Standard cytotherapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Phase 1, SAR445877, FOlfox6, Bevacizimab, First Line Treatment, Metastatic Colorectal Cancer (CRC), Microsatellite Stable
Interventions
SAR445877, FOLFOX6, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Interventions
Panitumumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Capecitabine, Quality-of-Life Assessment, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Temple, Texas
Conditions
Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
Interventions
radiation therapy, surgery, mFOLFIRINOX, FOLFOX
Radiation · Procedure · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
154
States / cities
Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
Conditions
Colorectal Cancer
Interventions
capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
119
States / cities
Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more
Conditions
Cancer
Interventions
BMS-690514 / FOLFIRI, BMS-690514 / FOLFOX
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Conditions
Pancreatic Cancer
Interventions
FOLFOXA
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Providence, Rhode Island
Conditions
Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions
Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,031 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
27
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more
Conditions
Stomach Neoplasms, Esophageal Neoplasms
Interventions
5-fluorouracil, Oxaliplatin, Leucovorin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Conditions
Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Interventions
BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
Drug
Lead sponsor
Bold Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Santa Monica, California • Tampa, Florida
Conditions
Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions
Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Santa Monica, California + 5 more
Conditions
Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
Interventions
GLP1-RA (semaglutide)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Locally Advanced Rectal Cancer
Interventions
Intensity-modulated radiation therapy, 5-fluorouracil, Leucovorin, Oxaliplatin, Capecitabine, Accelerated Radiation Therapy, Irinotecan
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Miami, Florida
Conditions
Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions
Regorafenib
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Including Dallas, TX, Ocala, FL, Denver, CO, Florida
Conditions
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Multigated Acquisition Scan, Oxaliplatin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 162 more
Conditions
Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
Interventions
Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Leucovorin
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Bullhead City, Arizona • Cerritos, California • Los Angeles, California + 6 more